299 related articles for article (PubMed ID: 24394749)
21. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
22. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
Persoons P; Vermeire S; Demyttenaere K; Fischler B; Vandenberghe J; Van Oudenhove L; Pierik M; Hlavaty T; Van Assche G; Noman M; Rutgeerts P
Aliment Pharmacol Ther; 2005 Jul; 22(2):101-10. PubMed ID: 16011668
[TBL] [Abstract][Full Text] [Related]
23. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
24. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
26. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
27. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
28. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
29. Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
D'Haens G; Reinisch W; Colombel JF; Panes J; Ghosh S; Prantera C; Lindgren S; Hommes DW; Huang Z; Boice J; Huyck S; Cornillie F;
J Crohns Colitis; 2017 Jun; 11(6):680-689. PubMed ID: 28025307
[TBL] [Abstract][Full Text] [Related]
30. Malignancy in Crohn's disease: incidence and clinical characteristics in Japan.
Mizushima T; Ohno Y; Nakajima K; Kai Y; Iijima H; Sekimoto M; Nishida T; Nezu R; Ito T; Doki Y; Mori M
Digestion; 2010; 81(4):265-70. PubMed ID: 20134166
[TBL] [Abstract][Full Text] [Related]
31. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
32. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.
Oussalah A; Chevaux JB; Fay R; Sandborn WJ; Bigard MA; Peyrin-Biroulet L
Am J Gastroenterol; 2010 May; 105(5):1142-9. PubMed ID: 20389296
[TBL] [Abstract][Full Text] [Related]
33. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
Papay P; Reinisch W; Ho E; Gratzer C; Lissner D; Herkner H; Riss S; Dejaco C; Miehsler W; Vogelsang H; Novacek G
Am J Gastroenterol; 2010 May; 105(5):1158-64. PubMed ID: 20010925
[TBL] [Abstract][Full Text] [Related]
34. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.
Biancone L; Orlando A; Kohn A; Colombo E; Sostegni R; Angelucci E; Rizzello F; Castiglione F; Benazzato L; Papi C; Meucci G; Riegler G; Petruzziello C; Mocciaro F; Geremia A; Calabrese E; Cottone M; Pallone F
Gut; 2006 Feb; 55(2):228-33. PubMed ID: 16120759
[TBL] [Abstract][Full Text] [Related]
35. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.
Nakahigashi M; Yamamoto T
Cytokine; 2011 Nov; 56(2):531-5. PubMed ID: 21820319
[TBL] [Abstract][Full Text] [Related]
36. Balancing the risks and benefits of prolonged use of infliximab.
Schölmerich J
Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
[No Abstract] [Full Text] [Related]
37. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
Seiderer J; Göke B; Ochsenkühn T
Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
[TBL] [Abstract][Full Text] [Related]
38. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
[TBL] [Abstract][Full Text] [Related]
39. Mucormycosis in a Crohn's disease patient treated with infliximab.
Wall GC; Leman BI
Digestion; 2009; 80(3):182-4. PubMed ID: 19776582
[TBL] [Abstract][Full Text] [Related]
40. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]